S. Pinson, A. Creange, S. Barbarot, J. F. Stalder, and Y. Chaix, Neurofibromatosis 1: recommendations for management, Ann Dermatol Vénéréol, vol.128, pp.567-575, 2001.

D. G. Evans, M. E. Baser, J. Mc-gaughran, S. Sharif, and E. Howard, Malignant peripheral nerve sheath tumours in neurofibromatosis 1, J Med Genet, vol.39, pp.311-314, 2002.

S. A. Rasmussen, Y. Q. Friedman, and J. M. , Mortality in neurofibromatosis 1: an analysis using U.S. death certificates, Am J Hum Genet, vol.68, pp.1110-1118, 2010.

P. F. Doorn, W. M. Molenaar, J. Buter, and H. J. Hoekstra, Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis, Eur J Surg Oncol, vol.21, pp.78-82, 1995.

R. E. Ferner and D. H. Gutmann, International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis, Cancer Res, vol.62, pp.1573-1577, 2002.

E. Bastiaannet, H. Groen, P. L. Jager, D. C. Cobben, and W. T. Van-der-graaf, The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis, Cancer Treat Rev, vol.30, pp.83-101, 2004.

V. Kumar, K. Nath, C. G. Berman, J. Kim, and T. Tanvetyanon, Variance of SUVs for FDG-PET/CT is greater in clinical practice than Under idéal study settings, Clin Nucl méd, vol.38, pp.175-182, 2013.

A. J. De-langen, A. Vincent, L. M. Velasquez, H. T. Van-tinteren, and R. Boellaard, Repeatability of 18 F-FDG uptake measurements in tumors :a metaanalysis, J Nucl Med, vol.53, pp.701-708, 2012.

L. Tessonnier, F. Sebag, F. F. Palazzo, C. Colavolpe, D. Micco et al., Does (18)-FDG PET/CT add diagnostic accuracy in incidentally identified non secreting adrenal tumors?, Eur J Nucl Med Mol Imaging, vol.35, pp.2018-2025, 2008.

M. Okada, T. Shimono, Y. Komeya, R. Ando, and Y. Kagawa, Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesion, Ann Nucl Med, vol.23, pp.349-354, 2009.

, National Institutes of Health Consensus Development Conference, Neurofibromatosis. Conference statement, vol.45, pp.575-578, 1998.

B. Bensaid, F. Giammarile, T. Mognetti, L. Galoisy-guibal, and S. Pinson, Intérêt de la scintigraphie au FDG 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1, Ann Dermatol Vénéréol, vol.134, pp.735-742, 2007.

L. Valeyrie-allanore, N. Ismaili, S. Bastuji-garin, J. Zeller, and J. Wechsler, Symptoms associated with malignancy of peripheral nerve sheath tumours: a retrospective study of 69 patients with neurofibromatosis 1, Br J Dermatol, vol.153, pp.79-82, 2005.

P. Mantaka, A. D. Strauss, L. G. Strauss, M. Moehler, and H. Goldschmidt, Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET), Anticancer Res, vol.19, pp.4443-4450, 1999.

M. R. Wick, P. E. Swanson, B. W. Scheithauer, and J. C. Manivel, Malignant peripheral nerve sheath tumor. An immunohistochemical study of 62 cases, Am J Clin Pathol, vol.87, pp.425-433, 1987.

C. C. Stucky, K. N. Johnson, R. J. Gray, B. A. Pockaj, and I. T. Ocal, Malignant peripheral Nerve Sheath tumors (MPNST): The Mayo clinic experience, Ann Surg Oncol, vol.19, pp.878-885, 2012.

A. A. King, M. R. Debaun, V. M. Riccardi, and D. H. Gutmann, Malignant peripheral nerve sheath tumors in neurofibromatosis 1, Am J Med Genet, vol.93, pp.388-392, 2000.

B. S. Ducatman, B. W. Scheithauer, D. G. Piepgras, H. M. Reiman, and D. M. Ilstrup, Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases, Cancer, vol.57, pp.2006-2021, 1986.

T. Tucker, P. Wolkenstein, J. Revuz, J. Zeller, and J. M. Friedman, Association between benign and malignant peripheral nerve sheath tumors in NF1, Neurology, vol.65, pp.205-211, 1999.

R. C. Ramanathan and J. M. Thomas, Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis, Eur J Surg Oncol, vol.25, pp.190-193, 1999.

J. M. Woodruff, Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis, Am J Med Genet, vol.89, pp.23-30, 1999.

T. R. Loree, J. H. North, B. A. Werness, R. Nangia, and A. P. Mullins, Malignant peripheral nerve sheath tumors of the head and neck: analysis of prognostic factors, Otolaryngol Head Neck Surg, vol.122, pp.667-672, 2000.

D. E. Porter, V. Prasad, L. Foster, G. F. Dall, and R. Birch, Survival in Malignant Peripheral Nerve Sheath Tumours: a comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours, Sarcoma, p.756395, 2009.

L. Pechoux, C. Pautier, P. Delannes, M. Bui, B. N. Bonichon et al., Clinical practice guidelines: 2006 update of recommendations for the radiotherapeutic management of patients with soft tissue sarcoma (sarcoma of the extremity, uterine sarcoma and retroperitoneal sarcoma, Cancer Radiother, vol.10, pp.185-207, 2006.

B. E. Demas, R. T. Heelan, J. Lane, R. Marcove, and S. Hajdu, Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease, AJR Am J Roentgenol, vol.150, pp.615-620, 1988.

D. Schepper, A. M. Ramon, F. A. Degryse, and H. R. , Magnetic resonance imaging of soft tissue tumors, J Belge Radiol, vol.75, pp.286-296, 1992.

B. H. Van-herendael, S. R. Heyman, F. M. Vanhoenacker, G. De-temmerman, and J. L. Bloem, The value of magnetic resonance imaging in the differentiation between malignant peripheral nerve-sheath tumors and nonneurogenic malignant soft-tissue tumors, Skeletal Radiol, vol.35, pp.745-753, 2006.

K. P. Banks, The target sign: extremity, Radiology, vol.234, pp.899-900, 2005.

J. R. Crim, L. L. Seeger, L. Yao, V. Chandnani, and J. J. Eckardt, Diagnosis of softtissue masses with MR imaging: can benign masses be differentiated from malignant ones, Radiology, vol.185, pp.581-586, 1992.

S. B. Knight, D. Delbeke, J. R. Stewart, and M. P. Sandler, Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy, Chest, vol.109, pp.982-988, 1996.

V. J. Lowe, J. M. Hoffman, D. M. Delong, E. F. Patz, and R. E. Coleman, Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities, J Nucl Med, vol.35, pp.1771-1776, 1994.

M. Schmidt, M. Schmalenbach, M. Jungehulsing, P. Theissen, and M. Dietlein, 18F-FDG PET for detecting recurrent head and neck cancer, local lymph node involvement and distant metastases. Comparison of qualitative visual and semiquantitative analysis, Nuklearmedizin, vol.43, pp.91-104, 2004.

D. Cheng, A. Alavi, E. Lim, T. Werner, D. Bello et al., Dynamic changes of FDG Uptake and clearance in normal tissues, Mol Imaging Biol, vol.15, pp.345-352, 2013.

A. Frohlich, C. G. Diederichs, L. Staib, J. Vogel, and H. G. Beger, Detection of liver metastases from pancreatic cancer using FDG PET, J Nucl Med, vol.40, pp.250-255, 1999.

K. F. Hubner, E. Buonocore, H. R. Gould, J. Thie, and G. T. Smith, Differentiating benign from malignant lung lesions using ''quantitative'' parameters of FDG PET images, Clin Nucl Med, vol.21, pp.941-949, 1996.

V. S. Warbey, R. E. Ferner, J. T. Dunn, E. Calonje, and M. J. O'doherty, 18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1, Eur J Nucl Med Mol Imaging, vol.36, pp.751-757, 2009.

J. Miyamoto, K. Tatsuzawa, K. Owada, T. Kawabe, and H. Sasjima, Usefulness and limitations of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for detection of malignancy of orbital tumors, Neurol Med Chir (Tokyo), vol.48, pp.495-499, 2008.

M. R. Benz, J. Czernin, S. M. Dry, W. D. Tap, and M. S. Allen-auerbach, Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign, Cancer, vol.116, pp.451-458, 2010.

H. Otsuka, M. M. Graham, A. Kubo, and H. Nishitani, FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report, Ann Nucl Med, vol.19, pp.55-58, 2005.

Y. Santaella, I. Borrego, J. Lopez, M. J. Ortiz, and R. Vazquez, 18-FDG-PET in a case of recurrent malignant schwannoma, Rev Esp Med Nucl, vol.24, pp.127-130, 2005.

S. Chander, S. M. Westphal, I. T. Zak, D. A. Bloom, and A. P. Zingas, Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET, Clin Nucl Med, vol.29, pp.415-418, 2004.

S. B. Solomon, A. Semih-dogan, T. L. Nicol, J. N. Campbell, and M. G. Pomper, Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis, Clin Nucl Med, vol.26, pp.525-528, 2001.

S. Cardona, M. Schwarzbach, U. Hinz, A. Dimitrakopoulou-strauss, and N. Attigah, Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours, Eur J Surg Oncol, vol.29, pp.536-541, 2003.

W. Brenner, R. E. Friedrich, and K. A. Gawad, Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours, Eur J Nucl Med Mol Imaging, vol.33, pp.428-432, 2006.

L. I. Tsai, L. Drubach, F. Fahey, M. Irons, S. Voss et al., Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with mailgnant transformation, J Neurooncol, vol.108, issue.18, pp.469-475, 2012.

K. Karabatsou, T. R. Kiehl, D. M. Wilson, A. Hendler, and A. Guha, Potential role of (18)-Fluorodeoxyglucose positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1, Neurosurgery, vol.65, pp.160-170, 2009.

R. E. Ferner, J. D. Lucas, M. J. O'doherty, R. A. Hughes, and M. A. Smith, Evaluation of (18) fluorodeoxyglucose positron emission tomography ((18) FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1, J Neurol Neurosurg Psychiatry, vol.68, pp.353-357, 2000.

R. E. Ferner, J. F. Golding, M. Smith, E. Calonje, and J. W. , 18F) 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study, Ann Oncol, vol.19, pp.390-394, 2008.

E. Laffon, X. Adhoute, H. De-clermont, and R. Marthan, Is liver stable over time in 18 F-FDG PET imaging, J Nucl Med Technol, vol.39, pp.258-263, 2011.

K. R. Shahid, K. K. Amrami, R. J. Esther, V. J. Lowe, and R. J. Spinner, Falsenegative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of a neurofibromatosis type 1, J Surg Orthop Adv, vol.20, pp.132-135, 2011.

H. Meany, E. Dombi, J. Reynolds, M. Whatley, and A. Kurwa, 18-Fluorodeoxyglucose positron emission tomography FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST), Pediatr Blood Cancer, vol.60, pp.59-64, 2013.